\BOOKMARK [0][-]{chapter*.2}{Abstract}{}% 1
\BOOKMARK [0][-]{chapter*.3}{Acknowledgements}{}% 2
\BOOKMARK [0][-]{chapter*.4}{Declarations}{}% 3
\BOOKMARK [0][-]{chapter*.5}{Submitted Abstracts}{}% 4
\BOOKMARK [0][-]{chapter*.6}{Contents}{}% 5
\BOOKMARK [0][-]{chapter*.8}{List of Figures}{}% 6
\BOOKMARK [0][-]{chapter*.9}{List of Tables}{}% 7
\BOOKMARK [0][-]{chapter*.10}{Abbreviations}{}% 8
\BOOKMARK [0][-]{chapter.1}{Introduction}{}% 9
\BOOKMARK [1][-]{section.1.1}{Psoriasis and psoriatic arthritis}{chapter.1}% 10
\BOOKMARK [2][-]{subsection.1.1.1}{Epidemiology and global impact}{section.1.1}% 11
\BOOKMARK [2][-]{subsection.1.1.2}{Psoriasis and inflammatory dermatoses}{section.1.1}% 12
\BOOKMARK [2][-]{subsection.1.1.3}{PsA and spondyloarthropathies}{section.1.1}% 13
\BOOKMARK [1][-]{section.1.2}{Pathophysiology of psoriasis and psoriatic arthritis}{chapter.1}% 14
\BOOKMARK [2][-]{subsection.1.2.1}{Clinical presentation and diagnosis}{section.1.2}% 15
\BOOKMARK [2][-]{subsection.1.2.2}{Aetiology of psoriasis and PsA}{section.1.2}% 16
\BOOKMARK [2][-]{subsection.1.2.3}{Cell types involved in psoriasis and PsA pathogenesis}{section.1.2}% 17
\BOOKMARK [2][-]{subsection.1.2.4}{Therapeutic intervention}{section.1.2}% 18
\BOOKMARK [1][-]{section.1.3}{Genetics of psoriasis and psoriatic arthritis}{chapter.1}% 19
\BOOKMARK [2][-]{subsection.1.3.1}{Heritability}{section.1.3}% 20
\BOOKMARK [2][-]{subsection.1.3.2}{Non-GWAS and linkage studies}{section.1.3}% 21
\BOOKMARK [2][-]{subsection.1.3.3}{Genome-wide association studies}{section.1.3}% 22
\BOOKMARK [2][-]{subsection.1.3.4}{Relevance of non-coding variants in disease susceptibility}{section.1.3}% 23
\BOOKMARK [2][-]{subsection.1.3.5}{The role of GWAS studies in highlighting immune-relevant cell types and pathways}{section.1.3}% 24
\BOOKMARK [2][-]{subsection.1.3.6}{Limitations and future of GWAS studies}{section.1.3}% 25
\BOOKMARK [1][-]{section.1.4}{Functional interpretation of genome-wide association studies in complex diseases}{chapter.1}% 26
\BOOKMARK [2][-]{subsection.1.4.1}{Overcoming the limitations of GWAS: post-GWAS studies}{section.1.4}% 27
\BOOKMARK [2][-]{subsection.1.4.2}{Understanding the epigenetic landscape in complex diseases}{section.1.4}% 28
\BOOKMARK [2][-]{subsection.1.4.3}{The chromatin landscape}{section.1.4}% 29
\BOOKMARK [2][-]{subsection.1.4.4}{Transcriptional profiles in disease}{section.1.4}% 30
\BOOKMARK [2][-]{subsection.1.4.5}{Transcriptional regulation in complex diseases}{section.1.4}% 31
\BOOKMARK [2][-]{subsection.1.4.6}{Integration and interpretation of genomic data}{section.1.4}% 32
\BOOKMARK [2][-]{subsection.1.4.7}{The use of fine-mapping to prioritise functional causal variants}{section.1.4}% 33
\BOOKMARK [2][-]{subsection.1.4.8}{Approaches to establish disease mechanisms and causality of genetic variant}{section.1.4}% 34
\BOOKMARK [0][-]{chapter.2}{Material and Methods}{}% 35
\BOOKMARK [1][-]{section.2.1}{Ethical approval and recruitment of study participants}{chapter.2}% 36
\BOOKMARK [2][-]{subsection.2.1.1}{Psoriasis patient recruitment}{section.2.1}% 37
\BOOKMARK [2][-]{subsection.2.1.2}{PsA patient recruitment}{section.2.1}% 38
\BOOKMARK [2][-]{subsection.2.1.3}{Healthy volunteer recruitment}{section.2.1}% 39
\BOOKMARK [1][-]{section.2.2}{Sample processing}{chapter.2}% 40
\BOOKMARK [2][-]{subsection.2.2.1}{PBMCs and synovial fluid cells isolation}{section.2.2}% 41
\BOOKMARK [2][-]{subsection.2.2.2}{Skin biopsies processing and adherent assays}{section.2.2}% 42
\BOOKMARK [2][-]{subsection.2.2.3}{Fixation, cryopreservation and cell culture}{section.2.2}% 43
\BOOKMARK [2][-]{subsection.2.2.4}{Primary cell isolation using magnetic-activated cell sorting}{section.2.2}% 44
\BOOKMARK [2][-]{subsection.2.2.5}{Primary cell isolation using fluorescence-activated cell sorting}{section.2.2}% 45
\BOOKMARK [1][-]{section.2.3}{Experimental protocols}{chapter.2}% 46
\BOOKMARK [2][-]{subsection.2.3.1}{ATAC - Chromatin Accessibility}{section.2.3}% 47
\BOOKMARK [2][-]{subsection.2.3.2}{Chromatin immunoprecipitation with sequencing library preparation by Tn5 transposase}{section.2.3}% 48
\BOOKMARK [2][-]{subsection.2.3.3}{RNA extraction and gene expression quantification}{section.2.3}% 49
\BOOKMARK [2][-]{subsection.2.3.4}{DNA extraction and rs4672405 genotyping}{section.2.3}% 50
\BOOKMARK [2][-]{subsection.2.3.5}{Mass cytometry using cytometry by time of flight \(CyTOF\)}{section.2.3}% 51
\BOOKMARK [1][-]{section.2.4}{Computational and statistical analysis}{chapter.2}% 52
\BOOKMARK [2][-]{subsection.2.4.1}{ATAC data analysis}{section.2.4}% 53
\BOOKMARK [2][-]{subsection.2.4.2}{ChIPm data analysis}{section.2.4}% 54
\BOOKMARK [2][-]{subsection.2.4.3}{Gene expression analysis}{section.2.4}% 55
\BOOKMARK [2][-]{subsection.2.4.4}{Genomic region annotation, enrichment analysis, gene-network analysis and pathway visualisation }{section.2.4}% 56
\BOOKMARK [2][-]{subsection.2.4.5}{Statistical fine-mapping}{section.2.4}% 57
\BOOKMARK [2][-]{subsection.2.4.6}{Mass cytometry data analysis}{section.2.4}% 58
\BOOKMARK [0][-]{chapter.3}{Establishment of laboratory methods and analytical tools to assess genome-wide chromatin accessibility in clinical samples}{}% 59
\BOOKMARK [1][-]{section.3.1}{Introduction}{chapter.3}% 60
\BOOKMARK [2][-]{subsection.3.1.1}{Principle of ATAC-seq and compatibility with clinical samples}{section.3.1}% 61
\BOOKMARK [2][-]{subsection.3.1.2}{ATAC-seq limitations and advances in optimisation}{section.3.1}% 62
\BOOKMARK [2][-]{subsection.3.1.3}{Challenges of ATAC data analysis}{section.3.1}% 63
\BOOKMARK [2][-]{subsection.3.1.4}{The challenge of working with clinical samples}{section.3.1}% 64
\BOOKMARK [2][-]{subsection.3.1.5}{Aims}{section.3.1}% 65
\BOOKMARK [1][-]{section.3.2}{Results}{chapter.3}% 66
\BOOKMARK [2][-]{subsection.3.2.1}{Establishment of an ATAC-seq data analysis pipeline based on current knowledge}{section.3.2}% 67
\BOOKMARK [2][-]{subsection.3.2.2}{Assessment of ATAC-seq transposition times and comparison with Fast-ATAC protocol in relevant cell types}{section.3.2}% 68
\BOOKMARK [2][-]{subsection.3.2.3}{Limitations of ATAC-seq and FAST-ATAC to assess chromatin accessibility in KC}{section.3.2}% 69
\BOOKMARK [2][-]{subsection.3.2.4}{Effect of cryopreservation and fixation in the chromatin landscape of immune primary cells}{section.3.2}% 70
\BOOKMARK [1][-]{section.3.3}{Discussion}{chapter.3}% 71
\BOOKMARK [2][-]{subsection.3.3.1}{Studying the chromatin landscape from psoriasis biopsies}{section.3.3}% 72
\BOOKMARK [2][-]{subsection.3.3.2}{Characterisation of the effect of preservative techniques in the chromatin landscape}{section.3.3}% 73
\BOOKMARK [2][-]{subsection.3.3.3}{Conclusions}{section.3.3}% 74
\BOOKMARK [0][-]{chapter.4}{Defining the genome-wide chromatin accessibility landscape and gene expression profile in psoriasis}{}% 75
\BOOKMARK [1][-]{section.4.1}{Introduction}{chapter.4}% 76
\BOOKMARK [2][-]{subsection.4.1.1}{The systemic and skin-specific components in psoriasis}{section.4.1}% 77
\BOOKMARK [2][-]{subsection.4.1.2}{The personalised epigenome in disease}{section.4.1}% 78
\BOOKMARK [2][-]{subsection.4.1.3}{Transcriptional profiles in psoriasis}{section.4.1}% 79
\BOOKMARK [2][-]{subsection.4.1.4}{Chromatin accessibility, gene expression and genetic variability}{section.4.1}% 80
\BOOKMARK [2][-]{subsection.4.1.5}{Fine-mapping using summary stats}{section.4.1}% 81
\BOOKMARK [1][-]{section.4.2}{Aims}{chapter.4}% 82
\BOOKMARK [1][-]{section.4.3}{Results}{chapter.4}% 83
\BOOKMARK [2][-]{subsection.4.3.1}{Psoriasis and healthy controls: cohort description and datasets}{section.4.3}% 84
\BOOKMARK [2][-]{subsection.4.3.2}{Assessment of changes in the enhancer mark H3K27ac in psoriasis immune cells}{section.4.3}% 85
\BOOKMARK [2][-]{subsection.4.3.3}{Identifying global changes in immune cells chromatin accessibility between psoriasis patients and healthy controls}{section.4.3}% 86
\BOOKMARK [2][-]{subsection.4.3.4}{Gene expression analysis in psoriasis circulating immune cells}{section.4.3}% 87
\BOOKMARK [2][-]{subsection.4.3.5}{RNA-seq in epidermis from psoriasis patients}{section.4.3}% 88
\BOOKMARK [2][-]{subsection.4.3.6}{Comparison of the systemic and tissue-specific gene expression signatures in psoriasis}{section.4.3}% 89
\BOOKMARK [2][-]{subsection.4.3.7}{Integration of chromatin accessibility and expression data in circulating immune cells}{section.4.3}% 90
\BOOKMARK [2][-]{subsection.4.3.8}{Fine-mapping of psoriasis GWAS loci and functional interpretation}{section.4.3}% 91
\BOOKMARK [2][-]{subsection.4.3.9}{Maximising genetic commonalities across chronic inflammatory diseases: locus 2p15}{section.4.3}% 92
\BOOKMARK [1][-]{section.4.4}{Discussion}{chapter.4}% 93
\BOOKMARK [2][-]{subsection.4.4.1}{Chromatin accessibility and H3K27ac landscape in psoriasis immune cells}{section.4.4}% 94
\BOOKMARK [2][-]{subsection.4.4.2}{Dysregulation of gene expression in psoriasis circulating immune cells}{section.4.4}% 95
\BOOKMARK [2][-]{subsection.4.4.3}{Correlation between changes in chromatin accessibility and gene expression}{section.4.4}% 96
\BOOKMARK [2][-]{subsection.4.4.4}{Trancriptomic profiles in lesional and uninvolved psoriatic epidermis}{section.4.4}% 97
\BOOKMARK [2][-]{subsection.4.4.5}{LncRNAs in psoriasis}{section.4.4}% 98
\BOOKMARK [2][-]{subsection.4.4.6}{Differences in transcriptional dysregulation in blood and skin}{section.4.4}% 99
\BOOKMARK [2][-]{subsection.4.4.7}{Fine-mapping and the chr2p15 locus}{section.4.4}% 100
\BOOKMARK [2][-]{subsection.4.4.8}{Limitations in the approach and future work}{section.4.4}% 101
\BOOKMARK [2][-]{subsection.4.4.9}{Conclusions}{section.4.4}% 102
\BOOKMARK [0][-]{chapter.5}{Cross-tissue comparison of chromatin accessibility, gene expression signature and immunophenotypes in PsA}{}% 103
\BOOKMARK [1][-]{section.5.1}{Introduction}{chapter.5}% 104
\BOOKMARK [2][-]{subsection.5.1.1}{The relevance of cell type and tissue specificity in the study of PsA}{section.5.1}% 105
\BOOKMARK [2][-]{subsection.5.1.2}{Bulk transcriptomic studies in PsA and their limitations}{section.5.1}% 106
\BOOKMARK [2][-]{subsection.5.1.3}{Transcriptomics and proteomics at the single cell resolution}{section.5.1}% 107
\BOOKMARK [2][-]{subsection.5.1.4}{The challenges of using a multi-omics approach in the study of complex diseases}{section.5.1}% 108
\BOOKMARK [2][-]{subsection.5.1.5}{Integration of fine-mapping GWAS SNPs and functional data in PsA}{section.5.1}% 109
\BOOKMARK [1][-]{section.5.2}{Aims}{chapter.5}% 110
\BOOKMARK [1][-]{section.5.3}{Results}{chapter.5}% 111
\BOOKMARK [2][-]{subsection.5.3.1}{PsA patients cohort description and datasets}{section.5.3}% 112
\BOOKMARK [2][-]{subsection.5.3.2}{Immune cellular composition of blood and synovial fluid in the PsA cohort}{section.5.3}% 113
\BOOKMARK [2][-]{subsection.5.3.3}{Differential chromatin accessibility analysis in immune cells reveals differences between SF and PB}{section.5.3}% 114
\BOOKMARK [2][-]{subsection.5.3.4}{Pathway enrichment analysis highlights tissue functional differences in chromatin accessibility}{section.5.3}% 115
\BOOKMARK [2][-]{subsection.5.3.5}{Differential gene expression analysis in paired circulating and synovial immune cells}{section.5.3}% 116
\BOOKMARK [2][-]{subsection.5.3.6}{Characterisation of the CD14+ monocyte heterogeneity in PsA using scRNA-seq}{section.5.3}% 117
\BOOKMARK [2][-]{subsection.5.3.7}{Mass cytometry reveals differences in protein expression consistent with the chromatin accessibility and transcriptomic profile in PsA CD14+ monocytes.}{section.5.3}% 118
\BOOKMARK [2][-]{subsection.5.3.8}{Prioritisation and interpretation of PsA GWAS SNPs}{section.5.3}% 119
\BOOKMARK [1][-]{section.5.4}{Discussion}{chapter.5}% 120
\BOOKMARK [2][-]{subsection.5.4.1}{Characterising chromatin accessibility in PsA samples}{section.5.4}% 121
\BOOKMARK [2][-]{subsection.5.4.2}{Bulk gene expression profiling and integration with chromatin accessibility data}{section.5.4}% 122
\BOOKMARK [2][-]{subsection.5.4.3}{The relevance of monocytes and investigation of other cell types}{section.5.4}% 123
\BOOKMARK [2][-]{subsection.5.4.4}{Characterisation of monocytes by scRNA-seq}{section.5.4}% 124
\BOOKMARK [2][-]{subsection.5.4.5}{Mass cytometry in CD14+ monocytes and the integration with chromatin accessibility and transcriptomic data}{section.5.4}% 125
\BOOKMARK [2][-]{subsection.5.4.6}{Challenges and future perspectives in multi-omic approaches}{section.5.4}% 126
\BOOKMARK [2][-]{subsection.5.4.7}{The use of PsA functional data to inform fine-mapping GWAS loci}{section.5.4}% 127
\BOOKMARK [2][-]{subsection.5.4.8}{Conclusions}{section.5.4}% 128
\BOOKMARK [0][-]{subsection.5.4.8}{Appendices}{}% 129
\BOOKMARK [0][-]{appendix.A}{Tables}{}% 130
\BOOKMARK [1][-]{section.A.1}{Chapter 3 Tables}{appendix.A}% 131
\BOOKMARK [1][-]{section.A.2}{Chapter 4 Tables}{appendix.A}% 132
\BOOKMARK [1][-]{section.A.3}{Chapter 5 Tables}{appendix.A}% 133
\BOOKMARK [0][-]{appendix.B}{Additional figures}{}% 134
\BOOKMARK [1][-]{section.B.1}{Chapter 3 Figures}{appendix.B}% 135
\BOOKMARK [1][-]{section.B.2}{Chapter 4 Figures}{appendix.B}% 136
\BOOKMARK [1][-]{section.B.3}{Chapter 5 Figures}{appendix.B}% 137
\BOOKMARK [0][-]{appendix*.196}{Bibliography}{}% 138
